PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Gonzalez, Juan

Employees

1,400

Website

www.polypeptide.com

IPO Date

2021-04-28

Headquarters

Neuhofstrasse 24, Baar, Zug, 6340, Switzerland

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

PolyPeptide Group PPGN

PolyPeptide Group Earnings Call Summary

PolyPeptide Group Earnings

Transcripts

Events

About PolyPeptide Group AG

PolyPeptide Group
PPGN